We use cookies to measure traffic and show relevant ads. By clicking Accept you agree to our use of analytics and advertising cookies.
Intellia 公布了 CRISPR 疗法 lonvoguran ziclumeran 针对遗传性血管性水肿的 3 期长期期待结果。发作减少 87%，62% 的患者无需治疗。了解更多。
